April 23rd Pink Moon. The Pink Moon is, simply put, the full moon of spring. The name itself first came to the public in the 1930s when the Maine Farmer's Almanac published the Native American names of the Moon for each month. Pink Moon specifically referred to the full moon in April. That name itself is derived from the herb moss pink, one of the first flowers of spring in the eastern US. It does have other names in Native American traditions, ranging from Breaking Ice Moon to Moon When the Ducks Come Back and Moon When the Streams Are Again Navigable, SNAP is back at $11 WTF Moon among others, but Pink Moon is what caught on with the public.
Saturday. Howl at the moon! The world comes to terms with mother nature.. the great eclipse approaches. What does this magical moment mean for stocks? IDEA*--> HOWL. Werewolf Therapeutics to present data from studies of WTX-518, WTX-712 at AACR » 17:06 HOWL I feel lucky with this name.
We have: A) Presentations to be made at big event. B) Some Insider buying C) Werewolf Therapeutics expects cash to fund requirements through at least 2Q25 » 03/07 HOWL D) Werewolf Therapeutics initiated with bullish view at JMP Securities, here's why » 04:41 HOWL JMP Securities initiated… We have 3 or more reasons which means GREEN LIGHT!!!!! April 5-10, 2024 The AACR will host the AACR Annual Meeting 2024 at the San Diego Convention Center in San Diego, California fromApril 5-10, 2024. The AACR provides complimentary meeting registration to credentialed journalists and public information officers. Company Profile Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. YOUR GBA STOCK OF THE WEEK: HOWL Werewolf Therapeutics, Inc. $5.92-0.08(-1.33%)3:59 PM 04/05/24 NASDAQ |$USD |Post-Market:$5.70-0.22(-3.72%)7:59 PM
IT'S HERE! I have to take Mazda down to the service station for a slow leak in maybe two of my tires.... Put a pin in this until i get back~~~ Citi ups Mirion target, opens 'positive catalyst watch" » 07:25 MIR Watch last weeks buy of Natera they had a presentation. I woud bet it went very well.! NTRA Natera, Inc. $96.754.39(+4.75%)4:00 PM 04/05/24 NASDAQ |$USD |Pre-Market:$98.50+1.75(+1.81%)8:40 AM
MindMed to Present at Upcoming April Medical Conferences Apr 02, 2024 7:00 am EDT Download as PDF NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (Cboe Canada: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present posters describing the impact that COVID has had on the epidemiology of Generalized Anxiety Disorder at two upcoming medical conferences: European Psychiatric Association (EPA) 2024 Congress Title: Prevalence of Generalized Anxiety Disorder Among Five European Countries Before and During COVID Format: Poster Presenter: Phong Duong, PharmD Date and Time: Tuesday, April 9, 2024, at 9:30 AM Location: Budapest, Hungary Anxiety & Depression Association of America (ADAA) 2024 Conference Title: U.S. Generalized Anxiety Disorder Related To COVID-19 Pandemic Population by Age and Gender Format: Poster Presenter: Phong Duong, PharmD Date and Time: Friday, April 12, 2024, at 5:00 PM Location: Boston, MA